바이오로직스 자료
Breaking barriers in heterodimer formation with S-KiH platform technology
There’s growing market demand for bispecific antibody-based therapies thanks to their wide application in research and diagnostics, but many organizations face inherent challenges.
In this Whitepaper, we show how Samsung Biologics can overcome existing challenges through the ‘S-KiH platform,’ and how this innovative technology will be able to revolutionize the process of heterodimer formation.
There’s growing market demand for bispecific antibody-based therapies thanks to their wide application in research and diagnostics, but many organizations face inherent challenges.
In this Whitepaper, we show how Samsung Biologics can overcome existing challenges through the ‘S-KiH platform,’ and how this innovative technology will be able to revolutionize the process of heterodimer formation.